Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2014

View Archived Issues

Results from phase I trial of PF-06438179, a biosimilar to infliximab

ABP-501 proves equivalent to adalimumab in healthy volunteers

NNC-0151-0000 development halted, second-generation compound shows improved profile

Selexipag meets endpoint in pivotal phase III study in PAH

Inovio Pharmaceuticals expands license agreement with the University of Pennsylvania

Phase III perampanel trial meets primary endpoint in primary generalized tonic-clonic seizures

Isis Pharmaceuticals earns milestone payment under Biogen Idec collaboration

PsiOxus initiates phase I/II study of enadenotucirev for ovarian cancer

GW Pharmaceuticals reports expanded-access data for Epidiolex

Eculizumab receives U.S. orphan drug designation for myasthenia gravis

FDA award orphan drug designation to COTI-2 for ovarian cancer

Senhwa Biosciences begins phase I/II trial of CX-4945

Galapagos provides progress update on R&D programs

Bioequivalence of LY-2963016 to originator insulin glargine

GlaxoSmithKline presents new IFN-alpha inducers

GlaxoSmithKline describe novel DGAT1 inhibitors

Novel phosphodiesterase PDE10A inhibitors synthesized at Merck & Co.

Piramal Enterprises patents new proinflammatory cytokine inhibitors

Enrollment complete in phase IIa trial of GALE-301 immunotherapy in gynecological cancer

New IDO inhibitors prepared by Vertex Pharmaceuticals

Immunomodulator HMPL-523 enters first-in-human trial

Selecta Biosciences outlines pipeline progress and reveals new product candidate

Endocyte regains rights to vintafolide

Allergan acknowledges second unsolicited exchange offer from Valeant

BMS-817399 fails to improve rheumatoid arthritis in phase II proof-of-concept study

Takeda terminates development of orteronel for prostate cancer

Boehringer Ingelheim and Lilly resubmit empagliflozin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...